Video

ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Data from the following clinical trials are discussed:

    • 1373M0 - JUPITER-06: A randomized, double-blind, phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC) (JUPITER-06)
    • LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase 3 ORIENT-15 study (ORIENT-15)

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data